HER2 alterations (amplifications or mutations) were associated with poor overall survival (OS) in patients with metastatic disease in a retrospective dataset9 and HER2 overexpression was associated with increased risk of disease recurrence in patients with resected BTC13. This evidence concerns the gene ERBB2 and metastatic neoplasm.